Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (59)

2024

  1. Assessing the economic burden of vision loss and irreversible legal blindness in Spain (2021–2030): a societal perspective

    Health Economics Review, Vol. 14, Núm. 1

  2. Caregiver Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration

    Ophthalmic Research, pp. 516-527

  3. Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

    Ophthalmic research, Vol. 67, Núm. 1, pp. 311-321

  4. Suitability of machine learning for atrophy and fibrosis development in neovascular age-related macular degeneration

    Acta Ophthalmologica, Vol. 102, Núm. 5, pp. e831-e841

  5. The Scavenging Activity of Coenzyme Q10 Plus a Nutritional Complex on Human Retinal Pigment Epithelial Cells

    International Journal of Molecular Sciences, Vol. 25, Núm. 15

2023

  1. Análisis coste-utilidad del modelo de unidad de terapia intravítrea (UTI) frente a la administración tradicional de terapia intravítrea

    Archivos de la Sociedad Española de Oftalmologia, Vol. 98, Núm. 11, pp. 619-626

  2. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study

    International Ophthalmology, Vol. 43, Núm. 12, pp. 4639-4649

2022

  1. Clinical Characterization of Inpatients with Acute Conjunctivitis: A Retrospective Analysis by Natural Language Processing and Machine Learning

    Applied Sciences (Switzerland), Vol. 12, Núm. 23

  2. Respuesta al comentario «El menosprecio de lo próximo», relativo al editorial «Inteligencia artificial y Oftalmología: Estado actual»

    Archivos de la Sociedad Española de Oftalmologia, Vol. 97, Núm. 7, pp. 418-419

2021

  1. COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease?

    Journal of Internal Medicine, Vol. 289, Núm. 1, pp. 116-120

  2. Challenges in diabetic macular edema management: An expert consensus report

    Clinical Ophthalmology, Vol. 15, pp. 3183-3195

  3. Inteligencia artificial y oftalmología: estado actual

    Archivos de la Sociedad Española de Oftalmologia, Vol. 96, Núm. 8, pp. 399-400

  4. Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid

    Scientific Reports, Vol. 11, Núm. 1

  5. Recommendations for ophthalmologic practice during the easing of COVID-19 control measures

    Acta Ophthalmologica, Vol. 99, Núm. 7, pp. e973-e983

2020

  1. A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study

    PharmacoEconomics - Open, Vol. 4, Núm. 4, pp. 615-624

  2. Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach

    European Journal of Ophthalmology, Vol. 30, Núm. 5, pp. 1042-1052

2019

  1. Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice

    PLoS ONE, Vol. 14, Núm. 10

  2. First-line treatment algorithm and guidelines in center-involving diabetic macular edema

    European Journal of Ophthalmology, Vol. 29, Núm. 6, pp. 573-584

2018

  1. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials

    JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677

2016

  1. Molecular basis of factor H R1210C association with ocular and renal diseases

    Journal of the American Society of Nephrology, Vol. 27, Núm. 5, pp. 1305-1311